Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical CBRN Defense Consortium, 5250 [2021-01051]

Download as PDF khammond on DSKJM1Z7X2PROD with NOTICES 5250 Federal Register / Vol. 86, No. 11 / Tuesday, January 19, 2021 / Notices filed by Universal Electronics, Inc. (‘‘UEI’’) of Scottsdale, Arizona. 85 FR 31211–212 (May 22, 2020). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 (‘‘Section 337’’), in the importation into the United States, sale for importation, or sale in the United States after importation of certain electronic devices, including streaming players, televisions, set top boxes, remote controllers, and components thereof, by reason of infringement of one of more of the asserted claims of the ’196 patent and U.S. Patent No. 7,696,514 (‘‘the ’514 patent’’); 9,911,325 (‘‘the ’325 patent’’); 7,589,642 (‘‘the ’642 patent’’); 10,600,317 (‘‘the ’317 patent’’); and 9,716,853 (‘‘the ’853 patent’’). Id. The complaint also alleges that a domestic industry exists. Id. The Commission’s notice of investigation named the following respondents: Roku Inc. of Los Gatos, California; TCL Electronics Holdings Ltd. of New Territories, Hong Kong; Shenzhen TCL New Technology Co. Ltd. of Shenzhen, China; TCL King Electrical Appliances Co. Ltd., Huizhou, China; TTE Technology Inc. of Corona, California; TCL Corp. of Huizhou City, China; TCL Moka Int’l Ltd. of New Territories, Hong Kong; TCL Overseas Marketing Ltd. of New Territories, Hong Kong; TCL Industries Holdings Co., Ltd. of New Territories, Hong Kong; TCL Smart Device Co. of Bac Tan Uyen District, Vietnam; Hisense Co. Ltd. of Qingdao, China; Hisense Electronics Manufacturing Co. of America Corp. of Suwanee, Georgia; Hisense Import & Export Co. Ltd. of Qingdao, China; Qingdao Hisense Electric Co., Ltd. of Qingdao, China; Hisense International Co., Ltd. of Shen Wang, Hong Kong; Funai Electric Co., Ltd. of Osaka, Japan; Funai Corp. Inc. of Rutherford, New Jersey; and Funai Co., Ltd. of Nakhon Ratchasima, Thailand (collectively, ‘‘Respondents’’). Id. The Office of Unfair Import Investigations is not participating in this investigation. Id. The Commission previously terminated the investigation with respect to the ’853 patent, claims 19 and 20 of the ’196 patent, and claims 14 and 20 of the ’642 patent due to the withdrawal of those patent claims. Order No. 27 at 1 (Dec. 2, 2020), unreviewed by Comm’n Notice (Dec. 23, 2020). The Commission subsequently terminated the investigation with respect to claim 20 of the ’514 patent. Order No. 32 (Dec. 21, 2020), unreviewed by Comm’n Notice (Jan. 5, 2021). On December 29, 2020, the presiding administrative law judge issued the subject ID (Order No. 33), granting a VerDate Sep<11>2014 19:19 Jan 17, 2021 Jkt 253001 joint motion by UEI and Respondents to correct the notice of institution of the investigation by clarifying that claims 2 and 4–5 of the ’196 patent are domestic industry claims only and are not being asserted against any Respondent for purposes of infringement. No petition for review of the subject ID was filed. The Commission has determined not to review the subject ID. The notice of institution of the investigation is corrected accordingly. The Commission vote for this determination took place on January 13, 2021. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). By order of the Commission. Issued: January 13, 2021. Lisa Barton, Secretary to the Commission. [FR Doc. 2021–01083 Filed 1–15–21; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical CBRN Defense Consortium Notice is hereby given that, on January 8, 2021, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Medical CBRN Defense Consortium (‘‘MCDC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Aldevron, LLC, Fargo, ND; Applied Nanotech, Inc., Austin, TX; Clark Street Associates, Los Altos, CA; Encryptor, Inc., Plano, TX; Entasis Therapeutics, Waltham, MA; ImmunityBio, Inc., El Segundo, CA; Polaris Sensor Technologies, Huntsville, AL; Qorvo Biotechnologies, LLC, Bend, OR; Rigel Pharmaceuticals, San Francisco, CA; SafetySpect, Inc., Los Angeles, CA; and Somnio Global, LLC, Novi, MI have been added as parties to this venture. Also, 7 Hills Pharma, LLC, Houston, TX; ARMSTEL, Inc., Plano, TX; Captura PO 00000 Frm 00121 Fmt 4703 Sfmt 4703 Biopharma, Inc., Little Rock, AR; Chenega Reliable Services, LLC, San Antonio, TX; Data Intelligence Technologies, Inc., Arlington, VA; DEFTEC Corporation, Huntsville, AL; HDT Bio Corporation, Seattle, WA; MAE Group, LLC, Deerfield, NH; Metabiota, Inc., San Francisco, CA; Microscale Devices, LLC, Apex, NC; One Health Group, LLC, Chantilly, VA; Pathology Assist-Temp, Inc., Chantilly, VA; Peregrine Technical Solutions, LLC, Yorktown, VA; Profectus BioSciences, Inc., Baltimore, MD; TensorX, Inc., Vienna, VA and the University of Michigan, Ann Arbor, MI have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MCDC intends to file additional written notifications disclosing all changes in membership. On November 13, 2015, MCDC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on January 6, 2016 (81 FR 513). The last notification was filed with the Department on October 20, 2020. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on November 20, 2020 (85 FR 74386). Suzanne Morris, Chief, Premerger and Division Statistics, Antitrust Division. [FR Doc. 2021–01051 Filed 1–15–21; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Countering Weapons of Mass Destruction Notice is hereby given that, on January 7, 2021, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Countering Weapons of Mass Destruction (‘‘CWMD’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. E:\FR\FM\19JAN1.SGM 19JAN1

Agencies

[Federal Register Volume 86, Number 11 (Tuesday, January 19, 2021)]
[Notices]
[Page 5250]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-01051]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Medical CBRN Defense Consortium

    Notice is hereby given that, on January 8, 2021, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Medical CBRN Defense 
Consortium (``MCDC'') has filed written notifications simultaneously 
with the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Aldevron, LLC, Fargo, ND; Applied Nanotech, Inc., Austin, 
TX; Clark Street Associates, Los Altos, CA; Encryptor, Inc., Plano, TX; 
Entasis Therapeutics, Waltham, MA; ImmunityBio, Inc., El Segundo, CA; 
Polaris Sensor Technologies, Huntsville, AL; Qorvo Biotechnologies, 
LLC, Bend, OR; Rigel Pharmaceuticals, San Francisco, CA; SafetySpect, 
Inc., Los Angeles, CA; and Somnio Global, LLC, Novi, MI have been added 
as parties to this venture.
    Also, 7 Hills Pharma, LLC, Houston, TX; ARMSTEL, Inc., Plano, TX; 
Captura Biopharma, Inc., Little Rock, AR; Chenega Reliable Services, 
LLC, San Antonio, TX; Data Intelligence Technologies, Inc., Arlington, 
VA; DEFTEC Corporation, Huntsville, AL; HDT Bio Corporation, Seattle, 
WA; MAE Group, LLC, Deerfield, NH; Metabiota, Inc., San Francisco, CA; 
Microscale Devices, LLC, Apex, NC; One Health Group, LLC, Chantilly, 
VA; Pathology Assist-Temp, Inc., Chantilly, VA; Peregrine Technical 
Solutions, LLC, Yorktown, VA; Profectus BioSciences, Inc., Baltimore, 
MD; TensorX, Inc., Vienna, VA and the University of Michigan, Ann 
Arbor, MI have withdrawn as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MCDC intends to file additional 
written notifications disclosing all changes in membership.
    On November 13, 2015, MCDC filed its original notification pursuant 
to Section 6(a) of the Act. The Department of Justice published a 
notice in the Federal Register pursuant to Section 6(b) of the Act on 
January 6, 2016 (81 FR 513).
    The last notification was filed with the Department on October 20, 
2020. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on November 20, 2020 (85 FR 74386).

Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2021-01051 Filed 1-15-21; 8:45 am]
BILLING CODE P